Difference between revisions of "Tivantinib (ARQ-197)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 15: | Line 15: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:MET inhibitors]] | [[Category:MET inhibitors]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 23:12, 28 February 2020
General information
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.